The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCIR.L Regulatory News (CIR)

  • There is currently no data for CIR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block listing Interim Review

31 Mar 2021 12:14

RNS Number : 1477U
Circassia Group Plc
31 March 2021
 

Circassia Group plc

Block Listing Interim Review

 

Oxford, UK - 31 March 2021: Circassia Group plc ("Circassia" or "the Company") (LSE: CIR), a medical device company focused on respiratory diagnostics and monitoring, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:

 

Name of the company:

Circassia Group plc

Name of relevant scheme:

1) Circassia EMI Share Option Scheme

2) Circassia 2007 Unapproved Share Scheme

3) Circassia 2014 Performance Share Plan Scheme

4) Circassia 2015 Performance Share Plan Scheme

5) Circassia 2016 Performance Share Plan Scheme

6) Circassia 2017 Performance Share Plan Scheme

Period of return:

From:

1 October 2020

To:

31 March 2021

Balance of unallotted securities under scheme(s) from previous return:

1) 700,750

2) 203,000

3) 76,676

4) 251,864

5) 739,905

6) 678,980

Total: 2,651,175

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

1) - 6) inclusive: Nil

Less:  Number of securities issued/allotted under scheme(s) during period:

1) - 3) inclusive: Nil

4) (13,845)

5) (30,362)

6) (281,684)

Total: (325,891)

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

1) 700,750

2) 203,000

3) 76,676

4) 238,019

5) 709,543

6) 397,296

Total: 2,325,284

Number and class of securities originally listed and the date of admission:

1) 2,600,000 - 20 March 2014

2) 516,000 - 1 June 2017

3) 500,000 - 1 June 2017

4) 400,000 - 21 May 2018

5) 930,000 - 1 July 2019

6) 980,000 - 22 May 2020

 

For further information, please contact:

Circassia

Sarah Duncan, Company Secretary

 

Tel: +44(0)1865 405566

N+1 Singer (Nominated Adviser and Broker)

Aubrey Powell / Jen Boorer / Hannah Woodley

 

Tel: +44 (0) 20 7496 3000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRMZGFFMMZGMZM
Date   Source Headline
8th Jul 20195:02 pmRNSHolding(s) in Company
5th Jul 201912:07 pmRNSHolding(s) in Company
2nd Jul 20195:56 pmRNSHolding(s) in Company
2nd Jul 20195:56 pmRNSHolding(s) in Company
2nd Jul 20195:55 pmRNSHolding(s) in Company
1st Jul 20194:55 pmRNSHolding(s) in Company
28th Jun 20197:00 amRNSTotal Voting Rights
25th Jun 20194:57 pmRNSBlock Listing Application
17th Jun 20194:35 pmRNSPrice Monitoring Extension
7th Jun 20196:00 pmRNSHolding(s) in Company
7th Jun 20194:18 pmRNSResult of AGM
6th Jun 20196:23 pmRNSHolding(s) in Company
6th Jun 20194:11 pmRNSHolding(s) in Company
31st May 20197:00 amRNSTotal Voting Rights
28th May 20195:58 pmRNSHolding(s) in Company
28th May 20195:56 pmRNSHolding(s) in Company
21st May 20199:05 amRNSHolding(s) in Company
14th May 20194:24 pmRNSAnnual report and notice of AGM
8th May 20197:00 amRNSPublication of Tudorza Phase IV ASCENT in JAMA
3rd May 20192:18 pmRNSIssue of Equity
1st May 20197:00 amRNSFinal Results
30th Apr 20197:00 amRNSTotal Voting Rights
15th Apr 201911:55 amRNSHolding(s) in Company
1st Apr 20197:00 amRNSFDA approval of Duaklir for treatment of COPD
29th Mar 20194:40 pmRNSSecond Price Monitoring Extn
29th Mar 20194:35 pmRNSPrice Monitoring Extension
29th Mar 20193:58 pmRNSFDA website posts Duaklir NDA approval
29th Mar 20193:34 pmRNSCircassia announces FDA approval of Tudorza sNDA
29th Mar 20197:00 amRNSTotal Voting Rights
5th Mar 20194:53 pmRNSHolding(s) in Company
4th Mar 20194:04 pmRNSHolding(s) in Company
28th Feb 20197:00 amRNSTotal Voting Rights
11th Feb 20195:17 pmRNSHolding(s) in Company
8th Feb 20199:00 amRNSNotice of Results
6th Feb 20194:44 pmRNSHolding(s) in Company
6th Feb 20197:00 amRNSHolding(s) in Company
4th Feb 20195:57 pmRNSHolding(s) in Company
4th Feb 20198:06 amRNSSuccessful FDA Presubmission Meeting for AirNOvent
4th Feb 20198:06 amRNSAdmission to AIM
1st Feb 20194:36 pmRNSPrice Monitoring Extension
1st Feb 20194:03 pmRNSHolding(s) in Company
31st Jan 20197:00 amRNSTotal Voting Rights
30th Jan 20195:30 pmRNSCircassia Pharmaceuticals
30th Jan 20194:41 pmRNSSecond Price Monitoring Extn
30th Jan 20194:35 pmRNSPrice Monitoring Extension
28th Jan 20193:30 pmRNSHolding(s) in Company
28th Jan 20193:30 pmRNSHolding(s) in Company
25th Jan 201911:49 amRNSHolding(s) in Company
24th Jan 20197:00 amRNSCommercial rights acquired from AIT Therapeutics
18th Jan 20192:22 pmRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.